6:52 PM
 | 
Jul 24, 2012
 |  BC Extra  |  Clinical News

Sarepta jumps on clinical outcome data for eteplirsen

Sarepta Therapeutics Inc. (NASDAQ:SRPT) jumped $5.06 (146%) to $8.52 on Tuesday after reporting that once-weekly 50 mg/kg IV eteplirsen led to significantly better clinical outcomes at week 36 compared with placebo as evaluated by a six-minute walk test in an extension of a Phase IIb trial to treat Duchenne muscular dystrophy (DMD). Sarepta (formerly AVI...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >